---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-011360"
form_type: "8-K"
ticker: "ABVC"
cik: "0001173313"
company_name: "ABVC BIOPHARMA, INC."
filed_at: "2024-02-08T23:59:59+00:00"
generated_at: "2026-06-06T05:23:40.365480+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# ABVC BioPharma acquires $2.96M Taiwan land via stock & warrants in related-party deal

## Summary
- Land valued at ~$2.96M; consideration is 703,495 restricted shares at $3.50/share plus 5-yr warrants for 1M shares at $2.00.
- Seller Shuling Jiang is a director, holds ~10% of ABVC stock, and is married to the Chief Strategic Officer.
- Land to be used for GAP plant factories for botanical drug raw materials; closing targeted by March 10, 2024.
- Stock issuance exempt under Section 4(a)(2) and Regulation S; no registration for the unregistered shares.

## SEC filing metadata
- accession: 0001213900-24-011360
- form_type: 8-K
- ticker: ABVC
- cik: 0001173313
- company_name: ABVC BIOPHARMA, INC.
- filed_at: 2024-02-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1173313/000121390024011360/0001213900-24-011360-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1173313/000121390024011360/ea193134-8k_abvcbio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-011360
- JSON: https://secwatch.observer/filing/0001213900-24-011360.json
- Plain text: https://secwatch.observer/filing/0001213900-24-011360.txt

## Key facts
- Material Agreements
  ABVC BIOPHARMA, INC. entered into Agreement with Shuling Jiang valued at approximately $2,962,232 (effective 2024-02-06).
  - Action: entry
  - Counterparty: Shuling Jiang
  - Value: approximately $2,962,232
  - Effective: 2024-02-06
  source text: On February 06, 2024, ABVC BioPharma, Inc. (the “ Company ”) entered into a definitive agreement with Shuling Jiang (“ Jiang ”), pursuant to which Jiang shall transfer the ownership of certain land she owns located at Taoyuan City, Taiwan (the “ Land ”) to the Company (the “ Agreement ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1173313/000121390024011360/0001213900-24-011360-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.